FINWIRES · TerminalLIVE
FINWIRES

Top Cryptocurrencies Fall; Bitcoin Drops Below $59,000 Level

By

Top cryptocurrencies fell Tuesday, with Bitcoin (BTC-USD) dropping below the $59,000 level.

The CoinDesk Market Index, which tracks dozens of digital assets including Bitcoin, fell almost 2.7% in the past 24 hours. The Nasdaq 100 rose 1.8%, the S&P 500 increased 0.8%, and the Dow Jones Industrial Average was up 0.2%.

Bitcoin dropped 2.9% to $58,655, according to CoinMarketCap data. The most popular cryptocurrency's 24-hour trading volume rose 0.3% to $32.31 billion.

Ethereum (ETH-USD), the second-largest digital asset by market value, declined 2.9% to $1,575.

XRP (XRP-USD) dropped 2.8%, BNB (BNB-USD) fell 2.6%, and Solana (SOL-USD) lost 3.2%. Dogecoin (DOGE-USD) declined 2.3%, and Cardano (ADA-USD) shed 1.9%.

The US 10-year Treasury yield stood at 4.418% at 3 p.m. ET Tuesday, up from 4.374% Monday, while the five-year yield rose to 4.186% from 4.142%.

The total market value of the cryptocurrency industry fell 2.5% in the past 24 hours to $2.04 trillion, with trading volume decreasing 9.4% to $75.35 billion.

Price: $58661.87, Change: $-1486.63, Percent Change: -2.47%

Related Articles

Wire

Genmab Says Epcoritamab Combination Boosts Progression-Free Survival in Phase 3 Lymphoma Trial

Genmab (GMAB) said that a Phase 3 study of epcoritamab combined with lenalidomide met its primary objective, helping adults with relapsed or refractory diffuse large B-cell lymphoma stay progression-free longer than those receiving standard therapy.The regimen cut the risk of disease progression or death by 60% under US censoring rules and 56% under censoring rules used outside the US, with both results statistically significant, Genmab said Monday in a statement.Genmab said the safety profile was consistent with what's known for each drug. The company and its partner, AbbVie (ABBV), plan to discuss the findings with global regulators.The ongoing Phase 3 trial is enrolling adults who received at least one prior systemic therapy and were not eligible for stem-cell transplant or CAR-T treatment.Genmab shares rose 2.2% in after-hours trading, and AbbVie eased 0.2%.

$ABBV$GMAB
Wire

Mama's Creations Commences Proposed Common Stock Offering

Mama's Creations (MAMA) said late Monday it has commenced a proposed, underwritten public offering of its common stock.The company said it plans to grant the underwriters a 30-day option to buy up to an additional 15% of the shares offered.It intends to use the offering net proceeds for working capital and general corporate purposes, the company added.Shares of Mama's Creations were down more than 10% in after-hours activity.

$MAMA
Wire

Concentrix Fiscal Q2 Earnings Fall, Revenue Rises; FY Outlook Cut; Shares Tumble After Hours

Concentrix (CNXC) reported fiscal Q2 non-GAAP net income late Monday of $2.63 per diluted share, down from $2.70 a year earlier.Four analysts polled by FactSet expected $2.64.Revenue in the three months ended May 31 rose to $2.46 billion from $2.42 billion a year earlier.Four analysts expected $2.47 billion.Concentrix expects fiscal Q3 non-GAAP EPS of $2.65 to $2.77 on revenue of $2.47 billion to $2.49 billion.Four analysts project EPS of $3.09 on revenue of $2.53 billion.The company lowered full-year EPS guidance to $10.83 to $11.18 on revenue of $9.93 billion to $10.03 billion. The previous forecast pegged EPS at $11.48 to $12.07 on revenue of $10.04 billion to $10.18 billion.Four analysts expect EPS of $11.71 on revenue of $10.11 billion.Concentrix shares fell 26% in after-hours trading.The company maintained its quarterly dividend of $0.36 a share, payable Aug. 4, to stockholders of record July 24.

$CNXC